$118.14 0.00 (0%)
2/10/2012 4:00 PM

Biogen Idec, Inc. (NASDAQ:BIIB)

CAPS Rating: 3 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Results 1 - 20 of 84 : 1 2 3 4 5 Next »

Recs

0
Member Avatar 2trpop (67.66) Submitted: 2/7/2012 10:05:17 AM : Outperform Start Price: $120.46 BIIB Score: -2.33

This one seems like cheating.

Recs

0
Member Avatar portefeuille (99.81) Submitted: 12/15/2011 10:56:38 PM : Outperform Start Price: $102.70 BIIB Score: +14.55

There are currently 270 BIIB shares in my "fund" with break-even of around 71.89 USD. http://caps.fool.com/Blogs/fund-trades/678775.

Recs

1
Member Avatar StockDocStan (< 20) Submitted: 9/7/2011 10:26:09 AM : Outperform Start Price: $91.91 BIIB Score: +15.52

The clear leader in the independent biotechs is NOT likely to stay independent for long. I expect a buyout by Roche or even Pfizer or Merck in the next 6 months.

Recs

1
Member Avatar macginty (< 20) Submitted: 7/30/2011 1:07:51 PM : Outperform Start Price: $105.91 BIIB Score: +8.86

I feel that Tysabri's proven track-record over the past five years, as a prime treatment for multiple sclerosis, is providing real and worthwhile results for a very significant number of people, who must live with this otherwise 'incurable' disease.

Recs

0
Member Avatar TomFoolNC (97.39) Submitted: 5/28/2011 3:35:19 PM : Outperform Start Price: $93.96 BIIB Score: +26.04

new mgt, cutting costs, refocusing investments

Recs

0
Member Avatar EclecticRecluse (76.51) Submitted: 5/5/2011 4:31:17 AM : Outperform Start Price: $95.84 BIIB Score: +23.06

Upward Momentum

Recs

0
Member Avatar noguarantees (61.95) Submitted: 12/8/2010 3:12:51 AM : Outperform Start Price: $67.30 BIIB Score: +66.29

BIIB is a good investment because it does not depend on reviews of brokers and experts such as Zacks. Take for example NKBP: Zacks gives it as "strong buy" for the past nine months, in fact NKBP continues to fall

Recs

0
Member Avatar gunterle (37.58) Submitted: 10/20/2010 11:04:02 AM : Outperform Start Price: $67.41 BIIB Score: +72.01

Trendspotter

Recs

0
Member Avatar syljtffreedom (94.39) Submitted: 10/7/2010 10:52:55 PM : Outperform Start Price: $57.05 BIIB Score: +91.30

takeover target!

Recs

0
Member Avatar Bigdog2020 (65.54) Submitted: 7/23/2010 3:04:48 PM : Outperform Start Price: $53.66 BIIB Score: +98.48

Great pipeline - 5 filings over next few years. Nimble size and new leadership will further focus this company and drive continued earnings growth.

Recs

0
Member Avatar gsabc (74.68) Submitted: 7/1/2010 3:49:38 PM : Outperform Start Price: $46.70 BIIB Score: +122.44

With the house in order, the pipeline chugging along and Icahn placated (one hopes), this should be a good long-term gainer.

Recs

0
Member Avatar elliotyoung (< 20) Submitted: 5/2/2010 12:53:39 AM : Outperform Start Price: $52.70 BIIB Score: +110.79

Buy. Good momentum and PEG.

Recs

0
Member Avatar watchit2 (< 20) Submitted: 2/17/2010 12:46:02 AM : Underperform Start Price: $55.31 BIIB Score: -91.75

Dr.Paolo Zamboni has made a huge breakthrough in Multiple Sclerosis research. Sales of Tysabri and Avonex will go down. Even the new drug, Fampridine will struggle.

http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20091120/W5_liberation_091121/20091121?s_name=W5

Patients with Multiple Sclerosis and banding together to get tested and treated for Chronic Cerebral Spinal Insufficiency (CCSVI). Clinical trials already show a strong correlation between MS and CCSVI. A surgery (angioplasty or stents) on jugular veins are dramatically reducing symptoms of MS.

http://ccsvivictory.club.officelive.com/ConflictsofInterest.aspx

Or, www.ctv.ca Search “CCSVI”

And www.ccsvivictory.club.officelive.com check “conflicts of interest” tab

Recs

0
Member Avatar jahjimhall (< 20) Submitted: 2/11/2010 4:59:10 PM : Underperform Start Price: $55.08 BIIB Score: -88.91

Cutting back on R&D to help short term earnings at the expense of long term earnings (Ichann infleuence). Not a good move with competitors moving into same space

Recs

0
Member Avatar kevinottofro (98.80) Submitted: 10/20/2009 12:00:16 PM : Outperform Start Price: $48.24 BIIB Score: +121.41

Low relative PE, good star ranking, PEG & 09 PE still below normal - bottom fishing 10/19.

Recs

0
Member Avatar erilis (< 20) Submitted: 6/17/2009 11:30:54 AM : Outperform Start Price: $52.19 BIIB Score: +78.42

Doing fairly well in the crisis, if they continue with the same management and research stays up-to-date it will have a good future

Recs

0
Member Avatar onegoodguy521 (20.88) Submitted: 5/28/2009 12:48:03 PM : Outperform Start Price: $50.85 BIIB Score: +81.00

Three to four companies looking to buy BIIB for new drug pipeline.

Recs

0
Member Avatar ELPisthebest (88.45) Submitted: 3/6/2009 7:15:56 PM : Underperform Start Price: $43.53 BIIB Score: -70.24

This stock will be one of the few companies who will benefit from Obama's Universal Healthcare

Recs

0
Member Avatar buckywildcat (< 20) Submitted: 1/11/2009 10:41:34 PM : Underperform Start Price: $46.80 BIIB Score: -98.52

Numerous competitors entering the MS therapeutic field with several potential oral drugs on the horizon. Significant loss of market share will erode BIIB revenues by 2010.

Recs

0
Member Avatar PrestigeWW (86.12) Submitted: 12/2/2008 3:29:37 AM : Outperform Start Price: $39.61 BIIB Score: +133.07

biotech will outperform in the long run

Results 1 - 20 of 84 : 1 2 3 4 5 Next »

Featured Broker Partners


Advertisement